These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32827835)

  • 1. Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants.
    Murata S; Shirakawa M; Sugawara Y; Shuto M; Sawata M; Tanaka Y
    Papillomavirus Res; 2020 Dec; 10():100205. PubMed ID: 32827835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.
    Chen W; Zhao Y; Xie X; Liu J; Li J; Zhao C; Wang S; Liao X; Shou Q; Zheng M; Saah AJ; Wei L; Qiao Y
    Vaccine; 2019 Feb; 37(6):889-897. PubMed ID: 30638797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
    Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
    Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults.
    Moreira ED; Palefsky JM; Giuliano AR; Goldstone S; Aranda C; Jessen H; Hillman RJ; Ferris D; Coutlee F; Vardas E; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Hum Vaccin; 2011 Jul; 7(7):768-75. PubMed ID: 21712645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
    Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
    J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
    Davis BM; Blake I; Panicker G; Meites E; Thompson G; Geis J; Bruden D; Fischer M; Singleton R; Unger ER; Markowitz LE; Bruce MG
    Vaccine; 2024 May; 42(14):3277-3281. PubMed ID: 38627144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study.
    Amend KL; Turnbull B; Zhou L; Marks MA; Velicer C; Saddier P; Seeger JD
    Hum Vaccin Immunother; 2022 Nov; 18(5):2073750. PubMed ID: 35714277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
    Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
    Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States.
    Bruce MG; Meites E; Bulkow L; Panicker G; Hurlburt D; Lecy D; Thompson G; Rudolph K; Unger ER; Hennessy T; Markowitz LE
    Vaccine; 2020 Sep; 38(42):6585-6591. PubMed ID: 32814639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J
    Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
    Eun BW; Bahar E; Xavier S; Kim H; Borys D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2184756. PubMed ID: 36896702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL).
    Popmihajlov Z; Pang L; Brown E; Joshi A; Su SC; Kaplan SS; Willis ED
    Hum Vaccin Immunother; 2018; 14(12):2916-2920. PubMed ID: 30024827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.